MSACL 2018 US Abstract

Topic: Proteomics

Protein Biomarker Immunoaffinity Mass Spectrometry: Enabling Translational Pharmacology of Biologics in Pharma

Hendrik Neubert (Presenter)
Pfizer Inc

Authorship: Hendrik Neubert
BioMedicine Design, Pfizer Inc

Short Abstract

Significant efforts are spent in the pharmaceutical industry to execute translational pharmacology strategies aiming to reduce costly compound attrition in phase 2 clinical trials. A key element is to develop a deep understanding of the properties of human drug targets early on in discovery phases as well as to predict and assess using clinical bioanalysis how targets are engaged by biologics. This leads to better target selection, improved prediction of drug exposure and clinical dosing regimen. To this end, the pharmaceutical industry has been applying quantitative protein mass spectrometry for over a decade now. This presentation will illustrate this development with case studies and share our future vision for quantitative protein biomarker mass spectrometry in biopharmaceutical research.

Long Abstract

Significant efforts are spent in the pharmaceutical industry to execute translational pharmacology strategies aiming to reduce costly compound attrition in phase 2 clinical trials. A key element is to develop a deep understanding of the properties of human drug targets early on in discovery phases as well as to predict and assess using clinical bioanalysis how targets are engaged by biologics. This leads to better target selection, improved prediction of drug exposure and clinical dosing regimen. To this end, the pharmaceutical industry has been applying quantitative protein mass spectrometry for over a decade now. This has been an incredible journey with growing adaptation and increasing number of practitioners and experts. Workflow advancements enabled improved robustness, assay sensitivity and throughput, new reagents for capture approaches, automation of key steps, to name a few. Alongside this technology advancement, the application space of immunoaffinity protein mass spectrometry proliferated to provide new capabilities thereby unlocking new bioanalytical opportunities. We have advanced capabilities from measuring soluble proteins to target engagement, moved from plasma to tissues including small biopsies, from soluble proteins to structural and membrane bound proteins and from concentration analysis to measuring protein synthesis rates. This presentation will illustrate this development with case studies and share our future vision for quantitative protein biomarker mass spectrometry in biopharmaceutical research.


References & Acknowledgements:


Financial Disclosure

DescriptionY/NSource
Grantsno
SalaryyesPfizer
Board Memberno
Stockyes Pfizer
Expensesno

IP Royalty: no

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no